# Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/treatment-frequency-and-dosing-interval-of-ranibizumab-and-aflibercept-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Alberto Ferreira,Alexandros Sagkriotis,Melvin Olson,Jingsong Lu,Charles Makin,F Milnes |
| Citations | 57 |
| DOI | 10.1371/journal.pone.0133968 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0133968&type=printable |
| OpenAlex ID | https://openalex.org/W2145661951 |
| PMID | 26208030 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Alexandros Sagkriotis](https://scholariq.org/researchers/alexandros-sagkriotis/)

## Paper journal

- [PLoS ONE](https://scholariq.org/journals/plos-one/)

## Paper primary topic

- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)

## Paper topics

- [Retinal Diseases and Treatments](https://scholariq.org/topics/retinal-diseases-and-treatments/)
- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Ophthalmology and Visual Impairment Studies](https://scholariq.org/topics/ophthalmology-and-visual-impairment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.